Anlotinib Hydrochloride: Multi-Target VEGFR2/PDGFRβ/FGFR1 Inhibitor for Anti-Angiogenic Research

Executive Summary: Anlotinib (hydrochloride) is a small-molecule tyrosine kinase inhibitor (TKI) that potently inhibits VEGFR2, PDGFRβ, and FGFR1 with IC₅₀ values of 5.6 ± 1.2 nM, 8.7 ± 3.4 nM, and 11.7 ± 4.1 nM, respectively (Lin et al., 2018). It suppresses endothelial cell migration and capillary tube formation in vitro and in vivo, outperforming sunitinib, sorafenib, and nintedanib in anti-angiogenic assays (Gene 2018). Pharmacokinetic studies demonstrate high oral bioavailability (41–77% in dogs), strong plasma protein binding (93% in humans), and extensive tissue distribution, including tumor and brain. APExBIO provides Anlotinib (hydrochloride) as catalog C8688 for research use, with validated protocols for endothelial and tumor models (APExBIO).

Biological Rationale

Angiogenesis is essential for tumor growth and metastasis. Tumor cells secrete pro-angiogenic factors such as VEGF, PDGF-BB, and FGF-2 to stimulate endothelial cell migration and capillary formation (Lin et al., 2018). VEGFR2, PDGFRβ, and FGFR1 are key tyrosine kinase receptors mediating these signals. Inhibiting these kinases blocks endothelial cell proliferation, migration, and survival, making them validated targets in cancer research. Small-molecule TKIs like anlotinib enable precise perturbation of angiogenic signaling, facilitating mechanistic and translational studies (Related: Best Practices for Anlotinib Workflow — this article provides updated quantitative benchmarks and comparative data, extending protocol optimization guidance).

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib hydrochloride inhibits VEGFR2, PDGFRβ, and FGFR1 tyrosine kinases at nanomolar concentrations (IC₅₀ 5.6–11.7 nM) (Lin et al., 2018). This inhibition blocks ligand-induced receptor phosphorylation and downstream ERK pathway signaling. Anlotinib suppresses VEGF/PDGF-BB/FGF-2-mediated endothelial cell migration and tube formation in EA.hy 926 cells. It also inhibits microvessel sprouting in rat aortic ring assays and reduces microvessel density in the chicken chorioallantoic membrane (CAM) assay. Compared to sunitinib, sorafenib, and nintedanib, anlotinib shows stronger inhibition of both receptor phosphorylation and angiogenic phenotypes. The compound's broad kinase selectivity profile makes it a next-generation tool for dissecting overlapping angiogenic pathways (Related: Mechanistic Insights and Translational Opportunities — this article focuses on translational workflow, while the present review quantifies comparative bench performance).

Evidence & Benchmarks

• Anlotinib inhibits VEGFR2 phosphorylation with an IC₅₀ of 5.6 ± 1.2 nM in cell-based assays (Gene 2018, Fig. 2B).
• PDGFRβ and FGFR1 are inhibited at IC₅₀ values of 8.7 ± 3.4 nM and 11.7 ± 4.1 nM, respectively (Gene 2018, Table 1).
• In EA.hy 926 endothelial cell migration assays, anlotinib reduces VEGF-induced migration by >70% at 100 nM (Gene 2018, Fig. 2A).
• Capillary-like tube formation is significantly impaired in vitro in a concentration-dependent manner (p < 0.01, n=3; 24 h, Matrigel, 37°C) (Gene 2018, Fig. 3).
• Anlotinib outperforms sunitinib, sorafenib, and nintedanib in inhibiting angiogenic endpoints in head-to-head cell and tissue assays (Gene 2018, Figs. 2–4).
• In rat PK studies, oral bioavailability is 28–58%; in dogs, 41–77% (administered at 1–10 mg/kg; LC-MS/MS quantification) (APExBIO Product Data).
• Plasma protein binding is 93% in humans (equilibrium dialysis, 37°C, pH 7.4) (APExBIO).
• Anlotinib demonstrates a high median oral LD₅₀ of 1735.9 mg/kg in 14-day toxicity studies, with no significant organ or genetic toxicity observed (APExBIO).

For further details on selectivity and translational impact, see Anlotinib Hydrochloride: Next-Generation VEGFR2/PDGFRβ/FGFR1 Inhibitor—this review complements the current article with in-depth PK/PD modeling.

Applications, Limits & Misconceptions

Anlotinib hydrochloride is widely used in:

• In vitro cell migration and tube formation assays (e.g., EA.hy 926, HUVEC).
• Ex vivo aortic ring sprouting and CAM angiogenesis models.
• Mechanistic studies of VEGFR2/PDGFRβ/FGFR1 signaling blockade.
• Pharmacokinetic and tissue distribution profiling in preclinical models.
• Optimization of anti-angiogenic workflows in tumor research.

Anlotinib is not approved for diagnostic or therapeutic use; it is for laboratory research only. It does not inhibit all receptor tyrosine kinases equally, and off-target effects should be empirically determined. High plasma protein binding may influence free drug concentrations in some assay systems.

Common Pitfalls or Misconceptions

• Anlotinib (hydrochloride) is not suitable for in vivo human use outside approved clinical trials or regulatory frameworks.
• It does not inhibit non-angiogenic kinases (e.g., EGFR, ALK) at sub-micromolar concentrations—selectivity must be considered.
• Assay results may differ in non-endothelial cell lines; efficacy is best characterized in validated angiogenesis models.
• High protein binding can reduce free (active) anlotinib in some serum-rich media.
• Storage above -20°C or repeated freeze-thaw cycles may degrade compound potency.

Workflow Integration & Parameters

For optimal results:

• Dissolve anlotinib hydrochloride in DMSO to 10 mM stock; store at -20°C.
• Use final DMSO concentration ≤0.1% in cell-based assays.
• Apply at 5–100 nM for migration/tube formation; titrate as needed for cell type and endpoint.
• Include controls with sunitinib, sorafenib, or nintedanib for benchmarking.
• Quantify kinase phosphorylation via Western blot or ELISA using validated antibodies.
• For PK/PD studies, collect plasma/tissue samples at defined intervals (e.g., 0.5, 2, 8, 24 h) post-dosing.

APExBIO’s Anlotinib hydrochloride (C8688) is supplied with full documentation and batch QC data. For troubleshooting and advanced protocol optimization, see Multi-Target Tyrosine Kinase Inhibitor Workflows—the present article benchmarks comparative efficacy, while the linked article details integration into custom assay systems.

Conclusion & Outlook

Anlotinib (hydrochloride) is a validated, high-potency inhibitor of VEGFR2, PDGFRβ, and FGFR1, enabling rigorous dissection of angiogenic signaling in cancer and vascular biology research. Its superior performance over other TKIs, robust PK profile, and low systemic toxicity make it a gold-standard research tool. APExBIO (C8688) provides high-purity anlotinib with detailed technical support for advanced laboratory workflows. Ongoing studies continue to refine its translational applications and mechanistic insights.